Second Genome, Janssen Biotech Partner to Develop Ulcerative Colitis Treatment

Second Genome, San Bruno, Calif.-based microbiome therapeutic products company, has announced a partnership with Janssen Biotech designed to develop a novel treatment for ulcerative colitis.

Advertisement

Johnson & Johnson Innovation Center and the Immunology Therapeutic Area of Janssen Research & Development will fund the research.

More Articles on Gastroenterology:
8 Statistics on Annual & Hourly Gastroenterologist Compensation
American College of Gastroenterology Responds to ‘The $2.7T Medical Bill’
Dr. Leslie Schoppe Joins Brownwood Regional Medical Center

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.